793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
D. Lorusso(Humanitas University), Mansoor Raza Mirza(Copenhagen University Hospital), J. Martin-Babau(Hôpital Privé Jacques Cartier), Alessandra Bologna(Azienda USL di Bologna), M.P. Barretina Ginesta(Catalan Institute for Water Research), F. Marmé(Heidelberg University), Jason A. Wampfler(University Hospital of Bern), David Cibula(Charles University), Jianqing Zhu(Zhejiang Cancer Hospital), K. Hasegawa(Saitama Medical University), V. Samouëlian(Centre Hospitalier de l’Université de Montréal), June‐Yong Lee(Yonsei University), Fernanda Cano Casarotto(Hospital Moinhos de Vento), Yoland Antill(Cabrini Hospital), Michelle Lightfoot(NYU Langone Health), T.J. Herzog(University of Cincinnati), K.D. Woodhouse(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ying Cui(Merck & Co., Inc., Rahway, NJ, USA (United States)), B.M. Slomovitz(Mount Sinai Medical Center), B.J. Monk(Florida Cancer Specialists & Research Institute)
Cited by 3
Abstract
Related Papers
No related papers found
Powered by citation graph analysis